Neumora Therapeutics, Inc. Common Stock (NMRA) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Neumora Therapeutics, Inc. Common Stock (NMRA) Earnings Overview
As of June 13, 2026, Neumora Therapeutics, Inc. Common Stock (NMRA) reported trailing twelve-month net income of -$222M, reflecting +5.2% year-over-year growth. The company earned $-1.24 per diluted share over the past four quarters.
Looking at the long-term picture, NMRA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$99M in fiscal 2020.
Neumora Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), INVA ($504M net income, 63.8% margin), AXSM (-$188M net income, -28.7% margin), NMRA has comparable earnings metrics. Compare NMRA vs ACAD →
NMRA Earnings vs Peers
Earnings metrics vs comparable public companies
NMRA Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$237M | +2.8% | -$241M | $-1.45 | - | - |
| 2024 | -$244M | -3.3% | -$263M | $-1.53 | - | - |
| 2023 | -$236M | -80.2% | -$188M | $-1.49 | - | - |
| 2022 | -$131M | +44.8% | -$136M | $-0.86 | - | - |
| 2021 | -$237M | -139.1% | -$237M | $-1.56 | - | - |
| 2020 | -$99M | - | -$96M | $-0.65 | - | - |
Download Data
Export NMRA earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in NMRA back in 2020?
Total return with dividends reinvested · 6+ years of data
Calculate ReturnsHow much would $100/month in NMRA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NMRA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNMRA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowNMRA — Frequently Asked Questions
Quick answers to the most common questions about buying NMRA stock.
What is NMRA earnings per share (EPS)?
NMRA trailing twelve-month (TTM) diluted EPS is $-1.24, reflecting +5.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Neumora Therapeutics, Inc. Common Stock's net income?
Neumora Therapeutics, Inc. Common Stock (NMRA) trailing twelve-month net income is $-222M as of 2025. Earnings grew +5.2% year-over-year.
Is NMRA profitable?
NMRA is not currently profitable on a TTM basis, reporting a net loss of $-222M. Net margin is N/A. Investors should monitor for a return to profitability.
What is NMRA's earnings growth rate?
NMRA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are NMRA's profit margins?
Neumora Therapeutics, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -121.2%.
Is NMRA growing earnings?
NMRA is growing earnings steadily. YoY EPS growth of +5.2% is consistent with the 5-year CAGR of N/A. TTM net income is $-222M.
What was NMRA's best earnings year?
Neumora Therapeutics, Inc. Common Stock's highest annual net income on record is $-99M, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were NMRA's earnings last quarter?
NMRA's most recent reported quarter was Q1 2026. Net income was $-53M with diluted EPS of $-0.30. For a full breakdown of all quarters, see the quarterly earnings table on this page.